2233-29-6

Usage

Uses

Used in Chemical Research:
2,3,4-Trimethylpyridine is used as a reference compound for establishing consistent vibrational assignments. This is crucial for statistical-thermodynamic calculations, which are essential in understanding the behavior of molecules and their interactions with other compounds.
In this application, 2,3,4-trimethylpyridine serves as a valuable tool for researchers to analyze and predict the properties of other pyridine derivatives and related compounds. This knowledge can be applied to further develop new materials, drugs, and chemical processes that rely on the unique characteristics of pyridine-based compounds.

InChI:InChI=1S/C8H11N/c1-6-4-5-9-8(3)7(6)2/h4-5H,1-3H3

Upstream product

• 91324-23-1 1-(1,4-dimethyl-1,2,5,6-tetrahydro-[3]pyridyl)-ethanone 
• 76621-35-7 4,5,6-trimethyl-pyridin-2-ol 
• 408314-12-5 6-chloro-2,3,4-trimethyl-pyridine 
• 847154-74-9 4,5,6-trimethylnicotinonitrile 
• 46830-83-5 1-(1-benzyl-4-methyl-1,2,5,6-tetrahydro-[3]pyridyl)-ethanone 
• 57206-62-9 4-(3-acetyl-4-hydroxy-4-methyl-piperidino)-butan-2-one 
• 217969-12-5 1,3,3-triethoxy-butane 
• 99799-93-6 3,4-dimethyl-5-oxo-hexanal 
• 1574-33-0 3-methylpent-3-en-1-yne 
• 75-36-5 acetyl chloride 
• 77-75-8 meparfynol 
• 50-00-0 formaldehyd 
• 67-64-1 acetone 
• 7647-01-0 hydrogenchloride 

Downstream Products

• 101870-74-0 2,3,4-trimethyl-pyridine-1-oxide 
• 143564-40-3 5-(methoxycarbonyl)pentyl 4,6-O-benzylidene-2,3-bis-O-(2-deoxy-3,4,6-tri-O-acetyl-2-phthalimido-β-D-glucopyranosyl)-β-D-galactopyranoside 
• 143564-44-7 5-(methoxycarbonyl)pentyl 2,4-di-O-benzoyl-3,6-bis-O-(2-deoxy-3,4,6-tri-O-acetyl-2-phthalimido-β-D-glucopyranosyl)-β-D-galactopyranoside 
• 173375-13-8 2-(4-hydroxy-3,5-di-tert-butylphenylthio)-4,6-dichloro-sym-triazine 
• 41461-10-3 1α,3β-diacetoxycholesta-5,7-diene 

Relevant academic research and scientific papers

Inhibitors of cell proliferation, angiogenesis, fertility, and muscle contraction

The invention concerns inhibitors of cell proliferation, angiogenesis, fertility, and muscle contraction, characterized by formula I wherein, X, Y and Z independently represent C or N; ------ is an optional double bond; n is 0 or 1; R1, R2, and R4 independently represent hydrogen, a chemical bond, C1-10 alkyl; C2-10 alkenyl; C2-10 alkinyl; aryl; aryl-C1-10 alkyl; C3-10 heterocyclyl; C5-10 heteroaryl; halo, CF3; NO2; NHC(O)R*, OR, said alkyl, alkenyl, alkinyl, aryl, arylalkyl, heterocyclyl, or heteroaryl being optionally substituted; R3, R5, and R6 independently represent hydrogen, C1-10alkyl; C2-10 alkenyl; C2-10 alkinyl; aryl; aryl-C1-10alkyl; C3-10 heterocyclyl; C5-10 heteroaryl; halo, CF3; NO2; NHC(O)R*, OR, said alkyl, alkenyl, alkinyl, aryl, heterocyclyl, or heteroaryl being optionally substituted; or R5 and R6 together form a 5- or 6-member aryl, heterocyclyl or heteroaryl group; R is hydrogen or C1-6 alkyl; R* is hydrogen, or C1-6 alkyl, or OH, wherein the optional substituents are preferably selected from the group of one to three OH, C1-6 alkyl, halo, NO2, C1-6 alkoxy, and CF3, or a pharmaceutically acceptable salt thereof.

(Bezimidazol-2-yl)-pyridinium compounds

(Benzimidazol-2-yl)-pyridinium compounds of the formula STR1 wherein A is --SR9, --SO3- or --S--SO3- ; R1 and R3 each is hydrogen or (C1 -C7)-alkyl; R2 is hydrogen, (C1 -C7)-alkyl, (C1 -C7)-alkoxy or a negatively charged oxygen atom; R4 is hydrogen or a negative charge; R5, R6, R7 and R8 each is hydrogen, (C1 -C7)-alkyl, aryl, halogen, cyano, nitro, formyl, (C2 -C7)-alkanoyl, arylcarbonyl, carboxy, carboxy-(C1 -C7)-alkyl, (C1 -C7)-alkoxycarbonyl, aryloxycarbonyl, aryl-(C1 -C7)-alkoxycarbonyl, (C1 -C7)-alkoxycarbonyl-(C1 -C7)-alkyl, carbamoyl, mono- or di-(C1 -C7)-alkylcarbamoyl, pyrrolidinocarbonyl, piperidinocarbonyl, carbamoyl-(C1 -C7)-alkyl, mono- or di-(C1 -C7)-alkylcarbamoyl-(C1 -C7)-alkyl, pyrrolidinocarbonyl-(C1 -C7)-alkyl, piperdinocarbonyl-(C1 -C7)-alkyl, hydroxy, (C1 -C7)-alkoxy, (C2 -C7)-alkanoloxy, aryloxy, arylcarbonyloxy, (C1 -C7)-alkoxycarbonyloxy, aryl-(C1 -C7)-alkoxycarbonyloxy, aryloxycarbonyloxy, carbamoyloxy, mono- or di-(C1 -C7)-alkylcarbamoyloxy, pyrrolidinocarbonyloxy, piperidinocarbonyloxy, hydroxy-(C1 -C7)-alkyl, trifluoromethyl, di-(C1 -C7)-alkoxymethyl or (C2 -C3)-alkylenedioxymethyl or two of these substituents which are adjacent jointly and together with the carbon atoms to which they are attached are a 5-, 6- or 7-membered ring; and R9 is (C1 -C20)-alkyl, (C3 -C7)-cycloalkyl, (C3 -C7)-alkenylalkyl, (C3 -C7)-alkynylalkyl, substituted (C3 -C7)- alkenyl-alkyl, aryl, aryl-(C1 -C7)-alkyl, hydroxy- (C2 -C7)-alkyl, (C1 -C7)-alkoxy- (C2 -C7)-alkyl, (C1 -C7)-alkoxycarbonyl- (C1 -C7)-alkyl, carboxy-(C1 -C7)-alkyl, di-(C1 -C7)-alkoxycarbonyl-(C2 -C7)-alkyl, dicarboxy-(C2 -C7)-alkyl, carboxy-(C1 -C7)-alkylcarbamoyl-(C1 -C7)-alkyl, optionally N-substituted amino-(C2 -C7)-alkyl, optionally N-substituted amino-carboxy-(C2 -C7)-alkyl, optionally N-substituted amino-(C1 -C7)-alkoxycarbonyl-(C2 -C7)-alkyl, heteroaryl, heteroaryl-(C1 -C7)-alkyl or a residue derived from a cysteine-containing oligopeptide by elimination of the SH group; provided that when there is a net single positive charge there is an external anion, or a pharmaceutically acceptable acid addition salt thereof.

An Improved Liquid-Phase Synthesis of Simle Alkylpyridines

The synthesis of pyridines from mixtures of aldehydes or ketones and NH3 in the liquid phase has been reinvestigated, using continuous dosage of the carbonyl components to the reaction mixture.The main product from the reaction of acetaldehyde and formaldehyde is 3-methylpyridine (6), which is also the main product from the reaction of acrolein or a mixture of crotonaldehyde and formaldehyde under the same conditions.The reaction of other aldehydes with formaldehyde give 3,5-dialkylpyridines, e.g. 10, 16.Acetone reacts with either formaldehyde or acetaldehyde to give polysubstituted alkylpyridines.A mechanistic pathway is proposed which accounts for the formation of the observed products.

Process for the preparation of 24,24-difluoro-1α,25-dihydroxy vitamin D3 and intermediates obtained therefrom

The present invention relates to a process and intermediates for the preparation of 24,24-difluoro-1α,25-dihydroxycholecalciferol from the readily-available 1α,3β-dihydroxyandrost-5-en-17-one which is made by a known microbiological process from 3β-hydroxyandrost-5-en-17-one [R. M. Dodson, A. H. Goldkamp and R. D. Muir, J. Amer. Chem. Soc. 82 4026 (1960)].